Immedica Pharma US Inc.
Records under this name other than the patents Immedica Pharma US Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 28 patents it holds.
Back to Immedica Pharma US Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,673,093 | Method and Composition for Treating Arginase 1 Deficiency now held by Immedica Pharma AB In force · Medium confidence | In force | Medium confidence | |
| US 12,331,335 | Methods for Production of Human Recombinant Arginase 1 and Uses Thereof now held by Immedica Pharma AB In force · High confidence | In force | High confidence | |
| 12/115,169 | Therapeutic Compounds 570 Abandoned Abandoned Jul 4, 2011 | Abandoned | Abandoned Jul 4, 2011 | |
| 17/006,383 | Methods For Production Of Human Recombinant Arginase 1 And Uses Thereof held by Immedica Pharma AB Abandoned Abandoned Jun 27, 2023 | Abandoned | Abandoned Jun 27, 2023 | |
| 18/167,261 | Injectable Neurosteroid Formulations Containing Nanoparticles Abandoned Abandoned Jan 27, 2026 | Abandoned | Abandoned Jan 27, 2026 | |
| 18/328,996 | Use of Ganaxolone in Treating an Epilepsy Disorder Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/591,515 | Ganaxolone for Use in Treating Tuberous Sclerosis Complex Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/612,277 | Ganaxolone for Use in Treating Genetic Epileptic Disorders Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/625,718 | Ganaxolone for Use in Treatment of Established Status Epilepticus Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/731,812 | Amorphous Solid Dispersion Ganaxolone Formulation Abandoned Abandoned Mar 7, 2026 | Abandoned | Abandoned Mar 7, 2026 |